http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107286247-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2016-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107286247-B |
| titleOfInvention | The Dendritic Cells and application thereof of Chimeric antigen receptor modification containing anti-mesothelin single-chain antibody |
| abstract | The invention discloses a kind of Chimeric antigen receptor and its genes and recombinant expression carrier, the Dendritic Cells (mesoCAR-DC) of targeting mesothelin of engineering and application thereof, the Chimeric antigen receptor (mesoCAR) is GM-CSF-SS1scFv-CD8 α-CD40, in series by human GM-CSF signal peptide, anti-mesothelin single-chain antibody (anti-SS1scFv), people CD8 α hinge area, the transmembrane region of people CD40 and intracellular signal area.Using Chimeric antigen receptor mesoCAR of the invention dendritic cells in treatment progressive stage mesothelin positive modified cancer (especially cancer of pancreas) when, have good specific killing active in cancer cell. |
| priorityDate | 2016-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 371.